Purple Biotech (NASDAQ:PPBT) vs. Gemini Therapeutics (NASDAQ:GMTX) Financial Comparison

Gemini Therapeutics (NASDAQ:GMTX) and Purple Biotech (NASDAQ:PPBT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Profitability

This table compares Gemini Therapeutics and Purple Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Purple Biotech	N/A	-147.77%	-111.59%

Volatility & Risk

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Insider and Institutional Ownership

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Gemini Therapeutics and Purple Biotech”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87 million	($1.00)	-79.81
Purple Biotech	N/A	N/A	-$26.39 million	($23.25)	-0.07

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Gemini Therapeutics and Purple Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0	0	0	0	0.00
Purple Biotech	1	1	1	0	2.00

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 1,810.83%. Given Purple Biotech’s stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Gemini Therapeutics.

Summary

Purple Biotech beats Gemini Therapeutics on 6 of the 11 factors compared between the two stocks.

About Gemini Therapeutics

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.